Current Report · Items 5.07 · 8-K

Kestra Medical Technologies, Ltd.

KMTSNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Filed Sep 10, 2026Accepted Sep 10, 2026, 5:16 PM EDTCIK 1877184Accession 0001193125-26-388057

Company context

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD. We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms, enhanced comfort and wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital soluti

Current securities

KMTSNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote

Item 5.07 Submission of Matters to a Vote of Security Holders. The Kestra Medical Technologies, Ltd. (the “Company”) 2026 annual general meeting of shareholders (the “2026 Annual Meeting”) was held on September 9, 2026. The total number of the Company’s common shares voted in person or by proxy at the 2026 Annual Meeting was 55,399,491, representing approximately 94.53% of the 58,603,121 shares that were outstanding and entitled to vote as of July 17, 2026, the record date of the 2026 Annual Meeting. Voting results for each matter submitted to a vote at the 2026 Annual Meeting are provided below. Proposal 1 - Election of Directors The shareholders elected each of the three persons named below to serve as Class II directors until the Company’s 2029 annual meeting of shareholders and until their successors are duly elected and qualified, with the vote totals as set forth in the table below: Nominee For Against Abstain Broker Non-Vote ─────────────────────────────────────────────────────────────────────────────────────── Raymond W. Cohen 37,334,685 10,779,640 34,843 7,259,323 Kevin Reilly 38,900,190 9,204,737 35,241 7,259,323 Traci S. Umberger 38,866,030 9,238,943 35,195 7,259,323 Proposal 2 - Ratification of Independent Registered Public Accounting Firm The shareholders ratified the appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2027, with the vote totals set forth in the table below: For Against Abstain ──────────────────────────────────────── 55,356,225 8,469 34,797